• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides.

作者信息

Spertini François, Perrin Yannick, Audran Régine, Pellaton Céline, Boudousquié Caroline, Barbier Nathalie, Thierry Anne-Christine, Charlon Vincent, Reymond Christophe

机构信息

Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

出版信息

J Allergy Clin Immunol. 2014 Jul;134(1):239-240.e13. doi: 10.1016/j.jaci.2014.04.001. Epub 2014 May 3.

DOI:10.1016/j.jaci.2014.04.001
PMID:24797422
Abstract
摘要

相似文献

1
Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides.用来自Bet v 1的连续重叠肽进行免疫治疗的安全性和免疫原性。
J Allergy Clin Immunol. 2014 Jul;134(1):239-240.e13. doi: 10.1016/j.jaci.2014.04.001. Epub 2014 May 3.
2
Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.2 个月贝他过敏原特异性免疫治疗对变应性鼻结膜炎患者的疗效：一项 2b 期研究的结果。
J Allergy Clin Immunol. 2016 Jul;138(1):162-8. doi: 10.1016/j.jaci.2016.02.044. Epub 2016 May 6.
3
Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients.色素脱失性聚合变应原免疫疗法的安全性及对报告症状的影响：一项对2927例儿科患者的回顾性研究
Pediatr Allergy Immunol. 2015 May;26(3):280-286. doi: 10.1111/pai.12347.
4
Allergen immunotherapy for birch pollen-allergic patients: recent advances.桦树花粉过敏患者的变应原免疫疗法：最新进展
Immunotherapy. 2016 May;8(5):555-67. doi: 10.2217/imt-2015-0027.
5
[Comparative study of the effectiveness of 2 methods of specific immunotherapy of pollinoses].[花粉症两种特异性免疫疗法有效性的比较研究]
Ter Arkh. 1986;58(4):120-3.
6
Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma.奥马珠单抗预处理可使患有重度过敏性哮喘的儿童和青年进行变应原免疫治疗。
Pediatr Allergy Immunol. 2014 Dec;25(8):829-32. doi: 10.1111/pai.12306. Epub 2014 Dec 18.
7
Allergen-specific immunotherapy for patients with atopic dermatitis sensitized to animal dander.变应原特异性免疫疗法治疗对动物皮屑过敏的特应性皮炎患者。
Immun Inflamm Dis. 2020 Jun;8(2):165-169. doi: 10.1002/iid3.291. Epub 2020 Mar 12.
8
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.每日一次使用5种草花粉片剂进行舌下免疫治疗季节性变应性鼻炎的最佳剂量、疗效及安全性。
J Allergy Clin Immunol. 2007 Dec;120(6):1338-45. doi: 10.1016/j.jaci.2007.07.046. Epub 2007 Nov 1.
9
Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation.皮下免疫治疗中用注册变应原草花粉制剂进行加速加量。
Int Arch Allergy Immunol. 2013;160(4):420-4. doi: 10.1159/000343026. Epub 2012 Nov 23.
10
High-dose sublingual immunotherapy in children at 8-year follow-up.儿童高剂量舌下免疫疗法的8年随访
Ann Allergy Asthma Immunol. 2009 Mar;102(3):259-60. doi: 10.1016/S1081-1206(10)60093-2.

引用本文的文献

1
Characterization of the clinical relevance and hypoallergenic peptides of the newly evidenced major allergen Hum j 1.新证实的主要过敏原Hum j 1的临床相关性及低致敏性肽的特性分析
Front Immunol. 2025 Jun 23;16:1588870. doi: 10.3389/fimmu.2025.1588870. eCollection 2025.
2
B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine model.B细胞表位肽免疫疗法可减轻热带无爪螨-小鼠模型中几丁质结合蛋白诱导的2型气道炎症。
Respir Res. 2025 Apr 9;26(1):129. doi: 10.1186/s12931-025-03207-8.
3
Peptide immunotherapy for aeroallergens.
变应原肽免疫疗法。
Allergy Asthma Proc. 2023 Jul 1;44(4):237-243. doi: 10.2500/aap.2023.44.230028.
4
Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?过敏性鼻炎：我们对变应原特异性免疫疗法了解多少？
Front Allergy. 2021 Oct 28;2:747323. doi: 10.3389/falgy.2021.747323. eCollection 2021.
5
Allergen Immunotherapy: Current and Future Trends.变应原免疫治疗：现状和未来趋势。
Cells. 2022 Jan 8;11(2):212. doi: 10.3390/cells11020212.
6
Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1.预防性给予非变应原性贝母 1 肽可减少主要桦树花粉变应原贝母 1 的过敏致敏。
Front Immunol. 2021 Oct 26;12:744544. doi: 10.3389/fimmu.2021.744544. eCollection 2021.
7
Peptide Allergen Immunotherapy: A New Perspective in Olive-Pollen Allergy.肽过敏原免疫疗法：橄榄花粉过敏的新视角
Pharmaceutics. 2021 Jul 2;13(7):1007. doi: 10.3390/pharmaceutics13071007.
8
Design, production and immunomodulatory potency of a novel allergen bioparticle.新型过敏原生物颗粒的设计、生产和免疫调节效力。
PLoS One. 2020 Dec 1;15(12):e0242867. doi: 10.1371/journal.pone.0242867. eCollection 2020.
9
[Recombinant allergens, peptides, and virus-like particles for allergy immunotherapy].用于过敏免疫疗法的重组变应原、肽和病毒样颗粒
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Nov;63(11):1412-1423. doi: 10.1007/s00103-020-03231-7. Epub 2020 Oct 23.
10
Past, present, and future of allergen immunotherapy vaccines.变应原免疫治疗疫苗的过去、现在和未来。
Allergy. 2021 Jan;76(1):131-149. doi: 10.1111/all.14300. Epub 2020 Apr 29.